Earnings summaries and quarterly performance for METTLER TOLEDO INTERNATIONAL INC/.
Executive leadership at METTLER TOLEDO INTERNATIONAL INC/.
Board of directors at METTLER TOLEDO INTERNATIONAL INC/.
BS
Brian Shepherd
Detailed
Director
DD
Domitille Doat-Le Bigot
Detailed
Director
EF
Elisha Finney
Detailed
Director
IZ
Ingrid Zhang
Detailed
Director
MK
Michael Kelly
Detailed
Director
PP
Pablo Perversi
Detailed
Director
RD
Roland Diggelmann
Detailed
Chair of the Board
TS
Thomas Salice
Detailed
Lead Independent Director
WW
Wolfgang Wienand
Detailed
Director
Research analysts who have asked questions during METTLER TOLEDO INTERNATIONAL INC/ earnings calls.
Joshua Waldman
Cleveland Research Company
6 questions for MTD
Also covers: A, BRKR, CRL +1 more
Michael Ryskin
Bank of America Merrill Lynch
6 questions for MTD
Also covers: A, ALGN, AVTR +28 more
Patrick Donnelly
Citi
6 questions for MTD
Also covers: A, AVTR, BIO +22 more
Vijay Kumar
Evercore ISI
6 questions for MTD
Also covers: A, ABT, AVTR +21 more
DA
Daniel Arias
Stifel, Nicolaus & Company, Incorporated
4 questions for MTD
Also covers: A, AVTR, CDXS +15 more
Jack Meehan
Nephron Research LLC
4 questions for MTD
Also covers: A, AVTR, BIO +17 more
Tycho Peterson
Jefferies
4 questions for MTD
Also covers: A, AVTR, BIO +22 more
Brandon Couillard
Wells Fargo & Company
3 questions for MTD
Also covers: A, AVTR, BIO +10 more
CW
Casey Woodring
JPMorgan Chase & Co.
3 questions for MTD
Also covers: A, BLLN, CRL +12 more
Doug Schenkel
Wolfe Research LLC
3 questions for MTD
Also covers: A, AVTR, BRKR +15 more
Luke Sergott
Barclays
3 questions for MTD
Also covers: A, AVTR, BRKR +19 more
MS
Matthew Sykes
Goldman Sachs Group Inc.
3 questions for MTD
Also covers: A, ADPT, AVTR +21 more
RV
Rachel Vatnsdal Olson
JPMorgan
3 questions for MTD
Also covers: A, ADPT, AKYA +14 more
Dan Arias
Stifel Financial Corp.
2 questions for MTD
Also covers: A, GH, ILMN +9 more
DL
Daniel Leonard
Stifel Financial Corp.
2 questions for MTD
Also covers: A, AVTR, BIO +15 more
JS
Jack Slevin
Jefferies Financial Group Inc.
2 questions for MTD
Also covers: AGL, AMN, ASTH +8 more
Josh Heinen
Baird
2 questions for MTD
CR
Catherine Ramsey
BTIG
1 question for MTD
Also covers: A, EXAS, RVTY
Catherine Schulte
Baird
1 question for MTD
Also covers: A, CSTL, EXAS +7 more
DL
Dan Leonard
UBS Group AG
1 question for MTD
Also covers: A, AVTR, BIO +9 more
Douglas Schenkel
Wolfe Research, LLC
1 question for MTD
Also covers: A, AVTR, BRKR +21 more
Recent press releases and 8-K filings for MTD.
MTD reports Q4 2025 results
MTD
Earnings
Guidance Update
- Mettler-Toledo reported Q4 sales of $1.1 billion, up 5% in local currency (8% reported USD) and 4% excluding acquisitions.
- Q4 adjusted operating profit was $363 million (+3%) with margin at 32.1% (–160 bps); adjusted EPS rose 8% to $13.36.
- For FY 2025, local currency sales grew 3%, adjusted operating profit declined 1%, margin contracted 140 bps, adjusted EPS increased 4%, and free cash flow was $878 million (99% conversion).
- 2026 guidance: local currency sales growth of ~4% (3.5% ex-acquisitions), operating margin up 60–70 bps ex-currency, and EPS of $46.05–$46.70 (+8–9%).
8 hours ago
Mettler-Toledo reports Q4 2025 results
MTD
Earnings
Guidance Update
- Q4 sales of $1.1 billion, up 5% in local currency and 8% reported; regional growth: Americas +7%, Europe +4%, Asia +4%.
- Adjusted EPS of $13.36, up 8% y/y; reported EPS $13.98 vs. $11.96 prior year.
- Adjusted operating margin of 32.1%, down 160 bps, impacted by $50 million of incremental tariffs and a 100 bp FX headwind.
- Free cash flow of $878 million, 99% conversion; DSO 35 days, ITO 4.2×.
- 2026 guidance: local currency sales growth ~4%; adjusted EPS $46.05–$46.70 (+8%–9%); Q1 adj EPS $8.60–$8.75 (+5%–7%).
9 hours ago
Mettler Toledo reports Q4 2025 results
MTD
Earnings
Guidance Update
- Q4 sales were $1.1 billion, up 5% in local currency (8% reported) with growth across regions: Americas +7%, Europe +4%, Asia +4%.
- Adjusted operating profit reached $363 million (+3% yoy) and operating margin was 32.1%, down 160 bps due to FX (-100 bps) and tariff costs (-190 bps headwind).
- Adjusted EPS was $13.36, an 8% increase, while reported EPS was $13.98 compared with $11.96 a year ago; tariffs reduced EPS by 7%.
- Full-year 2025 adjusted free cash flow totaled $878 million, representing 99% conversion of adjusted net income.
- 2026 guidance: full-year local currency sales growth of ~4%, operating margin up 60–70 bps excluding FX, adjusted EPS of $46.05–$46.70 (+8–9%); Q1 sales +~3%, EPS $8.60–$8.75 (+5–7%).
9 hours ago
Mettler-Toledo reports Q4 2025 results
MTD
Earnings
Guidance Update
- Mettler-Toledo’s Q4 2025 net sales increased 8% to $1.130 billion; GAAP EPS were $13.98, and non-GAAP adjusted EPS were $13.36 (+8%).
- Q4 adjusted operating profit was $363.0 million, up 3% year-over-year.
- For full year 2025, reported sales rose 4% to $4.026 billion, and adjusted EPS reached $42.73 (+4%).
- Management forecasts Q1 2026 local currency sales growth of 3% with adjusted EPS of $8.60–8.75, and for full-year 2026 expects local currency sales up 4% and adjusted EPS of $46.05–46.70.
1 day ago
Mettler-Toledo reports Q4 2025 results
MTD
Earnings
Guidance Update
- Mettler-Toledo reported Q4 2025 net sales of $1.130 billion (up 8% year-over-year) and GAAP diluted EPS of $13.98 (vs. $11.96 prior year); adjusted EPS was $13.36, an 8% increase.
- By region, Q4 2025 reported sales grew 7% in the Americas, 12% in Europe and 5% in Asia/Rest of World.
- Full year 2025 net sales rose 4% to $4.026 billion, GAAP EPS was $42.05 (vs. $40.48) and adjusted EPS reached $42.73, a 4% increase.
- Management forecasts Q1 2026 local currency sales growth of ~3% with adjusted EPS of $8.60–$8.75, and full year 2026 local currency sales up ~4% with adjusted EPS of $46.05–$46.70.
1 day ago
Mettler-Toledo outlines growth strategy and 2026 guidance at JPM Healthcare Conference
MTD
Guidance Update
- Mettler-Toledo generated $4 billion in revenue, with the majority of sales in #1 global market-share segments—over 70% in pharma/biopharma, food manufacturing, specialty chemicals, and low-double-digit exposure to bioprocessing.
- Key growth engines include the Spinnaker 6 digital sales program, SternDrive pricing initiative, Blue Ocean global IT/supply-chain harmonization, and Jetstream innovation framework to drive share gains and automation/digitalization.
- The service business accounts for ~25% of sales, underpinned by a $3 billion serviceable installed base; Mettler-Toledo aims to outpace company-wide growth through expanded coverage, targeted campaigns, and channel-partner acquisitions.
- Medium-term financial targets call for ≥6% annual sales growth, 100 bps of margin expansion, ≈100% net-income conversion to free cash flow, and mid-teens EPS growth via share repurchases.
- For 2026, the company guides ≈4% revenue growth (≈2.5% pricing, ≈1% organic volume, acquisition lift), expecting market stabilization and upside from onshoring/reshoring trends.
Jan 13, 2026, 12:30 AM
Mettler-Toledo outlines strategy at J.P. Morgan Healthcare Conference
MTD
Guidance Update
- Mettler-Toledo is a global leader in precision instruments with ~$4 billion in annual revenue, holding #1 market share in the majority of its segments; its portfolio comprises 56% laboratory instruments and 40% industrial products.
- The company focuses on high-value end markets—pharma/biopharma, food manufacturing, and specialty chemicals account for >70% of sales—with 16% of revenue from China and 17% from other emerging markets.
- Key growth drivers include the Spinnaker sales-and-marketing program (Wave 6 launched in 2024), the Jetstream innovation framework, and a service business that represents 25% of sales with a $3 billion serviceable market (currently one-third covered).
- Financial targets include ≥6% annual sales growth, ≥100 bps of margin expansion, converting ~100% of net income into free cash flow, and mid-teens EPS growth via share repurchases.
- The firm is mitigating a 6% EPS tariff headwind in 2026 (vs. 5% in 2025) with full offsets planned; key U.S. import exposures are now $30 million from China, >$100 million from Mexico, and <$100 million from Switzerland—any tariff refunds would be passed through to customers.
Jan 13, 2026, 12:30 AM
Mettler-Toledo outlines growth strategy and 2026 guidance at J.P. Morgan Healthcare Conference
MTD
Guidance Update
- Mettler-Toledo reported about $4 billion in revenue, leading market positions in precision instruments, with 60 % of sales in high-growth end markets such as pharma, food manufacturing, and specialty chemicals, and a presence in 140 countries.
- The company’s Spinnaker 6 program (launched in 2024) advances digitalization and big-data analytics—including the Top K lead-generation tool—and its Jetstream innovation process targets rapid new-product development; service represents 25 % of sales with a $3 billion addressable installed-base opportunity.
- Targets 100 basis points of annual margin expansion driven by 6 %+ organic sales growth, SternDrive global pricing, Blue Ocean IT integration, and supply-chain optimization (in-region manufacturing for flexibility).
- Guides 4 % sales growth in 2026, expecting replacement cycles to normalize and potential upside; tariff headwinds to EPS cut from 6 % to 4 % after a U.S.-Switzerland trade deal—full mitigation planned, with reclamation efforts if required—supported by an agile global supply chain.
Jan 13, 2026, 12:30 AM
Mettler Toledo presents end-market diversification, growth initiatives, and 2024 financial performance
MTD
- Diversified sales mix: Life Sciences ~40%, Food Manufacturing ~20%, Chemical ~13%, Other ~28% of total sales.
- Geographic distribution: Americas 42%, Europe 29%, Asia/ROW 29%; emerging markets represent ~33% of sales.
- Innovation and digitalization focus: Launch of Spinnaker 6 program leveraging AI, Big Data, and digital sensors; continued product and service enhancements including LabX software and predictive maintenance tools.
- Service growth driver: Services account for ~25% of sales, supported by iBase penetration, AI-driven analytics, upsell campaigns, and remote diagnostics to maximize customer uptime.
- Strong financial track record: FY 2024 net sales $3,872 M (+2% USD, +3% local), gross margin 61%, adjusted operating margin 31%, adjusted operating profit $1,200 M, adjusted EPS $41.11.
Jan 13, 2026, 12:30 AM
Mettler-Toledo previews FY2026 outlook at Citi Annual Global Healthcare Conference
MTD
Guidance Update
- The industrial segment delivered 10% organic growth in Q3 FY2025, with double-digit gains in the Americas and Europe and the first industrial growth in China in two years.
- For FY2026, management expects low- to mid-single-digit growth in both the core industrial and product inspection businesses, with organic growth closer to low single digits, excluding acquisition contributions.
- The lab division saw strong bioprocess and process analytics performance—driven by bioproduction and semiconductor ultra-pure water demand—while liquid-handling pipettes are expected to remain below corporate average growth.
- Service revenue runs at about $1 billion versus a $3 billion serviceable installed base, and the company aims for above-average service growth through targeted penetration initiatives.
- Q4 FY2025 margins face headwinds from 200 bps of tariffs and 70 bps of currency impacts, though tariff mitigation and organizational agility have offset much of the pressure.
Dec 3, 2025, 3:30 PM
Quarterly earnings call transcripts for METTLER TOLEDO INTERNATIONAL INC/.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more